Schizophrenia Research
Volume 77, Issue 2 , Pages 253-260 , 15 September 2005

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment

Preliminary data for three of the polymorphisms was presented as an abstract at the 2004 College of Psychiatric and Neurologic Pharmacists (CPNP) meeting in Chicago, IL April 9–11, 2004.

  • Jeffrey R. Bishop

      Affiliations

    • University of Iowa College of Pharmacy, Clinical and Administrative Division, S413 Pharmacy Building, Iowa City, IA 52242, USA
    • ,
  • Vicki L. Ellingrod

      Affiliations

    • University of Iowa College of Pharmacy, Clinical and Administrative Division, S413 Pharmacy Building, Iowa City, IA 52242, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 319 335 8837; fax: +1 319 353 5646.
    • ,
  • Jessica Moline

      Affiliations

    • University of Iowa College of Pharmacy, Clinical and Administrative Division, S413 Pharmacy Building, Iowa City, IA 52242, USA
    • ,
  • Del Miller

      Affiliations

    • University of Iowa Carver College of Medicine Department of Psychiatry, USA

Received 28 January 2005 ,Revised 24 March 2005 ,Accepted 4 April 2005.

References 

  1. Catlow JT, Barton RD, Clemens M, et al. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. Chromatogr. B. Biomed. Appl. 1995;668:85–90
  2. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997;37:205–237
  3. Egan MF, Straub RE, Goldberg TE, et al. Variation in nGRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. PNAS. 2004;101:12604–12609
  4. Ellingrod VL, Perry PJ, Lund BC, et al. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J. Clin. Psychopharmacol. 2002;22:622–623
  5. Evins AE, Amico E, Posever TA, et al. d-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 2002;56:19–23
  6. Fitzgerald LW, Deutch AY, Gasic G, et al. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 1995;15:2453–2461
  7. Fujii Y, Shibata H, Kikuta R, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor 3 gene (GRM3) with schizophrenia. Psychiatr. Genet. 2003;13:71–76
  8. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry. 1999;56:21–27
  9. Goff DC, Hennen J, Lyoo IK, et al. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol. Psychiatry. 2002;51:493–497
  10. Heresco-Levy U, Ermilov E, Shimoni J, et al. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry. 2002;159:480–482
  11. Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry. 2004;55:165–171
  12. Holden C. Excited by glutamate. Science. 2003;300:1866–1868
  13. Lahiri DK, Nurnburger JI. A rapid non-enzymatic method for the preparation of HMV DNA from blood for RFLP analysis. Nucleic Acids Res. 1991;19:544
  14. Marti SB, Cichon S, Propping P, et al. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am. J. Med. Genet. (Neuropsychiatric Genetics). 2002;114:46–50
  15. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 1992;258:597–603
  16. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J. Clin. Psychopharmacol. 1997;17:472–477
  17. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial. J. Clin. Psychopharmacol. 2001;21:14–20
  18. Riva, M.A., Tascedda, F., Lovati, E., 1997. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res. Mol. Brain Res. 50, 136-142.
  19. Scherer SW, Duvoisin RM, Kuhn R, et al. Localization of two metabotropic glutamate receptor genes, GRM3 and GRM8, to human chromosome 7q. Genomics. 1996;31:230–233
  20. Tascedda F, Blom JMC, Brunello N, Riva MA, et al. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol. Psychiatry. 2001;50:117–122

PII: S0920-9964(05)00135-0

doi: 10.1016/j.schres.2005.04.001

Schizophrenia Research
Volume 77, Issue 2 , Pages 253-260 , 15 September 2005

Article Tools